Skip to main content
. 2015 Apr 21;10(4):e0123619. doi: 10.1371/journal.pone.0123619

Fig 4. Evaluation of the treatment efficacy of delivery of CDDP with ALs and US.

Fig 4

(A) In vivo bioluminescence imaging on day 10. (B) Longitudinal analysis of normalized luciferase activity (n = 4 for each group). Values at different time points were normalized to those on day 3. Black arrows indicate the days on which treatment was administered (days 3, 4 and 7). On day 10, normalized luciferase activity in the CDDP + ALs + US group was significantly lower than that in the control group (P < 0.05) and showed a trend towards being lower than that in the US + ALs or CDDP + ALs group. Mean ± SEM values are shown. *P < 0.05.